UK starts real-time review of Moderna's COVID-19 vaccine candidate

Credit: REUTERS/PHIL NOBLE

Moderna Inc said on Tuesday United Kingdom's health regulator has started a real-time review of its experimental COVID-19 vaccine candidate.

Oct 27 (Reuters) - Moderna Inc MRNA.O said on Tuesday United Kingdom's health regulator has started a real-time review of its experimental COVID-19 vaccine candidate.

The company has begun a rolling data submission from its vaccine candidate to UK's Medicines and Healthcare products Regulatory Agency (MHRD) for it to start its independent assessment of evidence as and when it becomes available.

Such a process allows for a reduced time to approve a treatment, while maintaining the same standards of safety and effectiveness.

Moderna said earlier this month it was going to apply for real-time reviews of its experimental COVID-19 vaccine to Europe, following rolling reviews of shots of its rivals Pfizer Inc PFE.N and AstraZeneca AZN.L.

Canada's health ministry is also in the process of reviewing Moderna's COVID-19 vaccine candidate in real time, the company said earlier this month. (https://reut.rs/3kztkvr)

(Reporting by Trisha Roy in Bengaluru; Editing by Shinjini Ganguli)

((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 3635;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

MRNA PFE AZN

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More